This article is more than 5 years old. Information may no longer be current.

ProQR’s retinitis pigmentosa treatment gets orphan drug designation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

QR-1123, a first-in-class investigational antisense oligonucleotide for the treatment of vision loss associated with autosomal dominant retinitis pigmentosa, received an orphan drug designation from the FDA, ProQR announced in a press release.

“We are pleased to have orphan drug designation for our QR-1123 program targeting autosomal dominant retinitis pigmentosa, or adRP,” said Daniel de Boer, CEO of ProQR. “It highlights the unmet need for patients with this progressive disease-causing blindness. Our goal is to develop and actively advance a pipeline of programs that can treat inherited retinal diseases like adRP in a targeted manner.”

QR-1123, which is designed to be administered through intravitreal injections, aims to inhibit the toxic version of the rhodopsin protein by binding the P23H mutation in the RHO gene.

Discovered and developed by Ionis Pharmaceuticals, it was licensed by ProQR in 2018 and has since received IND clearance and a fast track designation from the FDA.